<DOC>
	<DOCNO>NCT00691184</DOCNO>
	<brief_summary>In study , safety pharmacokinetics 10 % terbinafine hydrogen chloride ( HCl ) nail lacquer wre investigate comparison vehicle control 1 % terbinafine cream</brief_summary>
	<brief_title>Safety Pharmacokinetics Terbinafine Hydrogen Chloride ( HCl ) Nail Lacquer Patients With Onychomycosis</brief_title>
	<detailed_description>This double-blind , randomize , parallel-design , placebo-controlled Phase 1 study compare 10 % Terbinafine HCl Nail Lacquer v . Placebo Nail Lacquer ( i.e. , vehicle control ) . For comparative purpose , study also include contemporaneous assessment 1 % Lamisil® Cream ( 1 % terbinafine HCl ) Lamisil® Tablets ( terbinafine HCl label 250 mg terbinafine ) . Forty ( 40 ) onychomycosis ( Groups 1 2 ) 16 tinea pedis ( Group 3 ) patient enrol 3 study center . In Group 1 , 10 % Terbinafine HCl Nail Lacquer , , Group 2 , vehicle ( 0 % terbinafine HCl ) , apply topically brush dose volume approximately 10 μL per nail twice daily 28 day toenail 5 mm adjacent skin . The patient visit study center Days 3 , 7 , 14 , 21 , 28 assessment clinical sign obtain blood sample . In addition , 24-hour urine sample collect assessed Day 28 Day 35 . Fifty six ( 56 ) patient ( 20 Group 1 , 20 Group 2 , 16 Group 3 ) receive single oral dose 250 mg Lamisil® Tablet 7-day washout period . For comparative purpose , study also evaluate local systemic safety , plasma level terbinafine , 3 major metabolite ( i.e. , desmethyl terbinafine , carboxybutyl terbinafine , desmethyl carboxybutyl terbinafine ) follow administration 1 % Lamisil® Cream comparison 10 % Terbinafine HCl Nail Lacquer . In Group 3 , approximately 0.5 g 1 % Lamisil® Cream apply twice day 7 day area foot affect tinea pedis . The patient visit study center Day 3 Day 7 assessment clinical sign collection blood sample . A 24-hour urine sample collect assessed Day 7 Day 14 .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Onycholysis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Patients require meet follow criterion order eligible entry study : Were 18 70 year age , race either sex ; Were good general health confirm medical history brief physical examination ; Groups 1 2 , present clinically diagnose stable exacerbate onychomycosis 25 % involvement one great toenail ; For Group 3 , mild tinea pedis ( mild tinea pedis define mild erythema , mild scaling , crack fissuring , mild burn pruritus ) ; For Groups 1 2 , least five toenail onycholysis ; For Groups 1 2 , positive calcofluor ( KOH ) exam must obtain Visit 1 specimen take affected great toenail ; Signed statement inform consent ; Were able understand requirement study , abide restriction , return required examination ; If female , meet one follow criterion : ( ) postmenopausal least one year , ( b ) hysterectomy tubal ligation , ( c ) use oral/systemic contraceptive intrauterine device least 28 day prior study entry throughout study , ( ) agree use spermicide combination barrier method contraception throughout study ; Had 10 toe nail could clip provide nail sample . Any follow excluded patient participate study : Any miss toe ; Known hypersensitivity terbinafine excipients nail lacquer ; Vital sign measurement clinically significantly outside normal limit ; Liver function test value two time upper limit normal clinical laboratory value , clinically significantly outside normal limit ; Receipt terbinafine tablet within 12 month terbinafine cream solution within six month prior screen ; Participation clinical trial systemic treatment onychomycosis within previous two month ; Current treatment rifampin , phenobarbital , phenytoin , carbamazepine , terfenadine , digoxin ; Prior treatment investigational drug within one month prior study start ; Diagnosis psoriasis history psoriasis ; Diagnosis serious concurrent disease might prevent completion trial ; Pregnancy ( confirmed pregnancy test ) , plan become pregnant within study period nursing ; Inability read , understand , sign inform consent form patient instruction apply remove study formulation ; Inability apply study medication ; Onychomycosis patient unwilling provide nail clipping ; Inability provide adequate blood sample ; Use nail polish product nail cosmetic product within seven day prior start treatment , unwilling discontinue use product course study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Onychomycosis , Toenail fungal infection , Terbinafine HCl , Pharmacokinetics</keyword>
</DOC>